Zurueck zur Suche

Reporte zur Charge U029623

Verknuepft ueber VAERS_ID mit VAERSDATA, Vax und Symptoms

9Reporte angezeigt
0Todesfaelle
0Hospitalisiert
0Lebensbedrohlich
0Bleibende Schaeden
TX 3 KS 1 VA 1 NY 1 GA 1 AR 1 CA 1

VAERS 2674495

MERCK & CO. INC. · HPV (GARDASIL 9) · Charge U029623

mild
Staat
KS
Alter
41,0
Geschlecht
F
Eingang
21.08.2023
Impfdatum
22.07.2023
Beginn
18.08.2023
Tage bis Beginn
27,0
Dosis
1
Route/Site
IM / LA
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: nein
Immediate post-injection reaction Injection site mass Injection site pain Injection site swelling Pain

Symptomtext

Soreness in left deltoid region felt late Friday night (8/18/23). As the weekend progressed, the soreness grew. It is uncomfortable to raise the arm and move around. There is noticeable swelling in the left deltoid compared to the right (dominant arm) and there is a palpable lump that was not felt before. Immediately after vaccination, there was superficial swelling into the inject safe bandage used when the bandage was removed that night. Otherwise, no issues (no soreness, swelling, itching, etc) with vaccination until 8/18/23.

Weitere VAERSDATA-Felder
Praegender Schweregrund
Injection site mass
Hospital-Tage
-
Labordaten
none at time of this report
Aktuelle Erkrankungen
none
Vorgeschichte
breast cancer in 2022
Andere Medikamente
tamoxifen 20mg once daily at night cetirizine 10mg once daily in the morning as needed
Allergien
none known
Vorherige Impfungen
-

VAERS 2427647

MERCK & CO. INC. · HPV (GARDASIL 9) · Charge u029623

mild
Staat
VA
Alter
38,0
Geschlecht
F
Eingang
02.09.2022
Impfdatum
24.08.2022
Beginn
24.08.2022
Tage bis Beginn
0,0
Dosis
1
Route/Site
IM / LA
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: nein
Injection site erythema Injection site pain Injection site swelling

Symptomtext

Site: Pain at Injection Site-Mild, Site: Redness at Injection Site-Mild, Site: Swelling at Injection Site-Mild

Weitere VAERSDATA-Felder
Praegender Schweregrund
Injection site erythema
Hospital-Tage
-
Labordaten
-
Aktuelle Erkrankungen
-
Vorgeschichte
-
Andere Medikamente
-
Allergien
-
Vorherige Impfungen
-

VAERS 2402279

MERCK & CO. INC. · HPV (GARDASIL 9) · Charge U029623

mild
Staat
NY
Alter
-
Geschlecht
F
Eingang
05.08.2022
Impfdatum
10.12.2021
Beginn
10.12.2021
Tage bis Beginn
0,0
Dosis
3
Route/Site
OT / LA
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: nein
Injection site pain Vaccination site erythema Vaccination site mass Vaccination site swelling Vaccination site warmth

Symptomtext

Vaccination site lump; Vaccination site redness; Vaccination site warmth; Vaccination site swelling; mild soreness at the injection site; mild soreness at the injection site; mild soreness at the injection site; This spontaneous report was received from a registered nurse, concerning a 36-year-old female patient. The patient's pertinent medical history included skin cancer diagnosed in 2012. The patient did not have any concomitant medications and drug reactions or allergies. On 10-DEC-2021, the patient was vaccinated with the first dose of hpv rl1 6 11 16 18 31 33 45 52 58 vlp vaccine (yeast) (GARDASIL 9) pre-filled syringe, in the left deltoid, at a dose of 0.5 milliliter (ml) by intramuscular route (lot number U008315, which was verified to be a valid lot number, expiration date reported and upon internal validation established as 15-AUG-2023), indication reported as "human papillomavirus (HPV) vaccine". Subsequently, she experienced mild soreness at the injection site that lasted a few days and then went away (vaccination site pain). On 25-FEB-2022 and 16-JUN-2022, she was vaccinated with the second and third dose of hpv rl1 6 11 16 18 31 33 45 52 58 vlp vaccine (yeast) (GARDASIL 9) pre-filled syringe, in the left deltoid, at a dose of 0.5 milliliter (ml) by intramuscular route (lot numbers U032636 and U029623, which were verified to be valid lot numbers, expiration dates not reported but upon internal validation established as 26-OCT-2023). The reporter further stated, the patient developed new onset of mild soreness at the injection site that lasted a few days and then went away (vaccination site pain) on unspecified dates in 2022 reported as "after the second and third dose of hpv rl1 6 11 16 18 31 33 45 52 58 vlp vaccine (yeast) (GARDASIL 9)". On 03-JUL-2022 reported as "approximately 2 weeks after the third dose of hpv rl1 6 11 16 18 31 33 45 52 58 vlp vaccine (yeast) (GARDASIL 9)", the patient experienced redness, warmth and swelling with a lump at the injection site (vaccination site erythema, vaccination site warmth, vaccination site swelling and vaccination site mass). The patient was advised to use cold compress. However, she contacted physician on 05-JUL-2022, as there was no improvement, she was still experiencing redness and swelling. At the time of the report, the outcome of the events vaccination site erythema, vaccination site warmth, vaccination site swelling and vaccination site mass was reported as not resolved. Causality assessment was not provided by the reporter.

Weitere VAERSDATA-Felder
Praegender Schweregrund
Injection site pain
Hospital-Tage
-
Labordaten
-
Aktuelle Erkrankungen
Skin cancer
Vorgeschichte
-
Andere Medikamente
-
Allergien
-
Vorherige Impfungen
-

VAERS 2260459

MERCK & CO. INC. · HPV (GARDASIL 9) · Charge U029623

mild
Staat
TX
Alter
17,0
Geschlecht
M
Eingang
02.05.2022
Impfdatum
19.04.2022
Beginn
19.04.2022
Tage bis Beginn
0,0
Dosis
1
Route/Site
IM / RA
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: ja
Pruritus Rash Respiratory tract congestion

Symptomtext

Minor presented with congestion, itching and rash to neck and arms 1-2 hours after administration of 1st series vaccines.

Weitere VAERSDATA-Felder
Praegender Schweregrund
Pruritus
Hospital-Tage
-
Labordaten
n/a
Aktuelle Erkrankungen
none
Vorgeschichte
none
Andere Medikamente
none
Allergien
none
Vorherige Impfungen
-

VAERS 2651315

MERCK & CO. INC. · HPV (GARDASIL 9) · Charge U029623

gering
Staat
GA
Alter
16,0
Geschlecht
F
Eingang
30.06.2023
Impfdatum
30.06.2023
Beginn
30.06.2023
Tage bis Beginn
0,0
Dosis
3
Route/Site
IM / LA
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: ja
Extra dose administered No adverse event

Symptomtext

No adverse event or symptoms demonstrated by patient. Patient was given 3rd dose of Gardasil 9 when it was not indicated. Patient had received first 2 doses before age 15 appropriately and was not immunocompromised, therefore it was not indicated to give 3rd dose that was administered in error today.

Weitere VAERSDATA-Felder
Praegender Schweregrund
Extra dose administered
Hospital-Tage
-
Labordaten
None
Aktuelle Erkrankungen
None
Vorgeschichte
None
Andere Medikamente
None
Allergien
None
Vorherige Impfungen
-

VAERS 2528126

MERCK & CO. INC. · HPV (GARDASIL 9) · Charge U029623

gering
Staat
AR
Alter
-
Geschlecht
M
Eingang
09.12.2022
Impfdatum
04.01.2018
Beginn
28.02.2019
Tage bis Beginn
420,0
Dosis
3
Route/Site
- / -
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: nein
Inappropriate schedule of product administration No adverse event

Symptomtext

No additional AE information; HCP called in to report that a consumer received their first dose of GARDASIL 9 on 01/04/2018, and second dose on 02/28/2019. Caller reports the patient was administered a third dose of GARDASIL 9 on 11/15/2022. No further information provided to fur; This spontaneous report was received from a nurse and refers to an 11-year-old male patient. His medical history was not reported. The patient's concurrent conditions were not reported. Concomitant therapies were not reported. On 04-JAN-2018, the patient was vaccinated with 1st dose of hpv rl1 6 11 16 18 31 33 45 52 58 vlp vaccine (yeast) (GARDASIL 9) injection, lot #U029623, expiration date: 26-OCT-2023 (strength, exact dose, site and route of administration were not provided) for prophylaxis. On 28-FEB-2019 and 15-NOV-2022, the patient received respectively second and third dose of hpv rl1 6 11 16 18 31 33 45 52 58 vlp vaccine (yeast) (GARDASIL 9) (Inappropriate schedule of product administration). No additional adverse event was reported.

Weitere VAERSDATA-Felder
Praegender Schweregrund
Inappropriate schedule of product administration
Hospital-Tage
-
Labordaten
-
Aktuelle Erkrankungen
-
Vorgeschichte
-
Andere Medikamente
-
Allergien
-
Vorherige Impfungen
-

VAERS 2391419

MERCK & CO. INC. · HPV (GARDASIL 9) · Charge U029623

gering
Staat
CA
Alter
17,0
Geschlecht
F
Eingang
26.07.2022
Impfdatum
25.07.2022
Beginn
26.07.2022
Tage bis Beginn
1,0
Dosis
1
Route/Site
IM / LA
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: nein
Incorrect dose administered Wrong product administered

Symptomtext

Ordered MMR and VZV separately. MMRV was given instead of MMR. Patient was also given VZV. so received two doses of VZV.

Weitere VAERSDATA-Felder
Praegender Schweregrund
Incorrect dose administered
Hospital-Tage
-
Labordaten
-
Aktuelle Erkrankungen
-
Vorgeschichte
-
Andere Medikamente
-
Allergien
-
Vorherige Impfungen
-

VAERS 2284436

MERCK & CO. INC. · HPV (GARDASIL 9) · Charge U029623

gering
Staat
TX
Alter
11,0
Geschlecht
U
Eingang
19.05.2022
Impfdatum
28.04.2017
Beginn
27.03.2018
Tage bis Beginn
333,0
Dosis
3
Route/Site
- / -
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: nein
Extra dose administered Inappropriate schedule of product administration No adverse event

Symptomtext

The caller did not definitively confirm the brand name for the previous HPV vaccines that were administered in 2017 and 2018; No additional AE reported; Patient inadvertently received a third dose of GARDASIL 9 on May 3, 2022 after completing a two dose regimen.; Patient inadvertently received a third dose of GARDASIL 9 on May 3, 2022 after completing a two dose regimen. Patient received their first dose of a HPV vaccine on April 28, 2017 and their second dose on March 27, 2018.; This spontaneous report was received from a medical assistant concerning a 12-year-old patient of unknown gender. The patient's concurrent conditions, pertinent medical history and concomitant medications were not provided. On 28-APR-2017, the patient was vaccinated with the first dose of Human Papillomavirus (HPV) vaccine (manufacturer unknown) for prophylaxis (Dose, route of administration, anatomical location, lot # and expiration date were not reported). On 27-MAR-2018, the patient received the second dose of HPV vaccine (manufacturer unknown) for prophylaxis (Dose, route of administration, anatomical location, lot # and expiration date were not reported) (Inappropriate schedule of product administration). On 03-MAY-2022, after completing a two dose regimen, the patient inadvertently received a third dose of HPV rL1 6 11 16 18 31 33 45 52 58 VLP vaccine (yeast) (GARDASIL 9) 0.5 mL once, lot # U029623, expiration date 26-OCT-2023, for prophylaxis (Route of administration and anatomical location were not provided) (Extra dose administered). The reporter mentioned that no adverse effects were noted after the administration of extra dose of HPV rL1 6 11 16 18 31 33 45 52 58 VLP vaccine (yeast) (GARDASIL 9) and no additional adverse events were reported (No adverse event).

Weitere VAERSDATA-Felder
Praegender Schweregrund
Extra dose administered
Hospital-Tage
-
Labordaten
-
Aktuelle Erkrankungen
-
Vorgeschichte
-
Andere Medikamente
-
Allergien
-
Vorherige Impfungen
-

VAERS 2263210

MERCK & CO. INC. · HPV (GARDASIL 9) · Charge U029623

gering
Staat
TX
Alter
16,0
Geschlecht
F
Eingang
04.05.2022
Impfdatum
03.05.2022
Beginn
03.05.2022
Tage bis Beginn
0,0
Dosis
3
Route/Site
IM / RA
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: nein
No adverse event

Symptomtext

No adverse effects know of

Weitere VAERSDATA-Felder
Praegender Schweregrund
No adverse event
Hospital-Tage
-
Labordaten
None
Aktuelle Erkrankungen
None
Vorgeschichte
None
Andere Medikamente
None
Allergien
None known
Vorherige Impfungen
-